Pan-PPAR agonists based on the resveratrol scaffold: biological evaluation and docking studies.
Li
Wei
W
Beijing Institute of Pharmacology and Toxicology, China.
He
Xinhua
X
Shi
Weiguo
W
Jia
Haoyan
H
Zhong
Bohua
B
D000818:Animals; D001665:Binding Sites; D045744:Cell Line, Tumor; D003198:Computer Simulation; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy; D004041:Dietary Fats; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D047493:PPAR alpha / Q000819:agonists* / Q000378:metabolism; D047494:PPAR delta / Q000819:agonists* / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D010421:Pentanoic Acids / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D000077185:Resveratrol; D013267:Stilbenes / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use
D004041:Dietary Fats; D047493:PPAR alpha; D047494:PPAR delta; D047495:PPAR gamma; D010421:Pentanoic Acids; D013267:Stilbenes; D000077185:Resveratrol